tirzepatide vs semaglutide reviews vs. tirzepatide vs semaglutide weight loss

Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p 3 pounds/week associated with higher risk

In addition, GLP-1 and its own receptors are synthesized in the same brain regions, strongly supporting the actions of this peptide on the CNS

Urva S et al (2021) Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

As well, genetic factors such as genetic variations in TCF7L2 genes may influence how long your body takes to lose weight

Therefore, metabolic improvements from acute and chronic administration of exendin-phe1 exceeded those of exendin-4